James Xu

James Xu

Goodwin

Contact
View Bio
RSS

Latest Posts › IP License

Share:

Similis Bio and Blau Farmaceutica Enter into Development and License Agreement for Biosimilars

On October 25, 2022, JSR Life Sciences and Blau Farmaceutica announced that Similis Bio, JSR Life Sciences’s business unit focused on biosimilar development, has signed its first development and license agreement with Blau...more

11/7/2022  /  Biosimilars , Development Agreements , IP License , Pharmaceutical Industry , Prescription Drugs
1 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide